Keyword: Trelegy Ellipta

Thanks to a market-share grab for triple-drug COPD therapy Trelegy Ellipta, GSK's respiratory strategy is working as planned.

Hoping to revive the case, AstraZeneca said it will submit results from another phase 3 trial that weren't originally included in its application.

AstraZeneca and GlaxoSmithKline have locked horns in their battle for respiratory supremacy. Could a trial win and an FDA nod help give AZ a leg up?

GKS's respiratory franchise holds its ground amid Advair generic attack, as its oncology business takes shape.

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

A handful of branded drug ads are using popular ‘70s light rock songs, both to aid recall and to reach older audiences with music from their youth.

GSK has data in hand that could help Trelegy move into the asthma arena—though it's not all positive.

Boehringer Ingelheim’s ad campaign for Ofev pulled away from GlaxoSmithKline’s Trelegy to land the #FierceMadness ad tournament crown.

The #FierceMadness final game is set—and it’ll be GlaxoSmithKline's Trelegy taking on Boehringer Ingelheim's Ofev for the 2019 title.

#FierceMadness DTC is down to Repatha versus Trelegy, while Aimovig will take on Ofev in a short round of voting that ends Tuesday at midnight.